ML-007C-MA
ML-007C-MA-221
Phase 2 small_molecule active
Quick answer
ML-007C-MA for Psychosis Associated With Alzheimer's Disease is a Phase 2 program (small_molecule) at MapLight Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- MapLight Therapeutics
- Indication
- Psychosis Associated With Alzheimer's Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active